Table 2

Comparison of clinical and pathological data of patients with anti-GBM disease with and without serum anti-C1q antibodies
Anti-C1q antibody positive (n = 15) Anti-C1q antibody negative (n = 10) P
Age (years) 34.0 ± 16.0 28.5 ± 9.8 0.342
Gender (male/female) 13/2 9/1 1.000
Hydrocarbon exposure 2/15 (13.3%) 1/10 (10%) 1.000
Prodromal infection 5/15 (33.3%) 5/10 (50%) 0.678
Smoker 6/15 (40%) 5/10 (50%) 1.000
Hemoptysis 6/15 (40%) 6/10 (60%) 0.428
Oliguria/anuria 8/15 (53.3%) 6/10 (60%) 1.000
Gross hematuria 6/15 (40%) 6/10 (60%) 0.428
Nephrotic syndrome 4/7 (57.1%) 2/4 (50%) 1.000
Serum creatinine (μmol/L) 1016.2 ± 340.0 954.1 ± 384.7 0.675
Interval from onset (days) 50.4 ± 33.4 46.0 ± 36.8 0.766
Level of anti-GBM antibodies (U/mL) 88.2 ± 49.0 89.2 ± 36.9 0.957
ANCA positive 2/15 (13.3%) 0/10 (0) 0.500
Hemoglobin (g/L) 78.2 ± 24.3 86.1 ± 34.3 0.506
Percentage of crescents in glomeruli (%) 100.0 (90.0-100.0) 88.5 (80.8-100.0) 0.210
 Cellular crescents (%) 85.5 (24.8-100.0) 75.0 (29.5-83.3) 0.462
 Fibrocellular crescents (%) 14.5 (0–50.0) 25.0 (16.8-68.0) 0.360
 Fibrotic crescents (%) 0 (0–2.3) 0 0.443
Positive C1q deposit in the kidney 4/15 (26.7%) 3/10 (30%) 1.000
Renal survival (1 year) 1/15 (6.7%) 1/10 (10%) 1.000
Patient survival (1 year) 10/15 (66.7%) 8/10 (80%) 0.659

GBM Glomerular basement membrane, ANCA Anti-neutrophil cytoplasmic antibodies.

Hu et al.

Hu et al. BMC Immunology 2013 14:42   doi:10.1186/1471-2172-14-42

Open Data